

Smart port.
Early detection.
Better outcomes.
THE NEXT GENERATION IN REMOTE PATIENT MONITORING
Advances in Personalized Medicine and Digital Health technologies are revolutionizing modern medicine. NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.

WHAT IS
NXGEN PORT?





Port efficacy + new sensor technology
Remotely measure real-time physiological distress
Digital health platform coordinating patients + providers
Early intervention
Patient management

THE
PROBLEM
COSTS $2.3 BILLION ANNUALLY
50%
Of patients on chemo with a port suffer from neutropenia which puts them at greater risk for infection and complications
20%
Of patients have complications ranging from minor to major, most frequently infections and thrombosis, leading to port removal, hospitalization, higher medical costs and treatment
25%
Of women on trastuzumab for HER2+ breast cancer suffer cardiotoxicity and cardiac function decline
50%
Of patients have to delay or cancel treatment due to poor blood counts on treatment days
THE
SOLUTION


1
REMOTE MONITORING
Physiologic changes and trends measured in vivo.


2
DATA + ANALYTICS
Real-time information about a patient's health status.

3
REPORT TO PROVIDER
Relevant measures and actionable data.

4
TAKE ACTION
Virtual patient management.
THE
VALUE
NXgen Port PROVIDES EARLY
INDICATION OF:
-
Infection
-
Changes in heart function
-
Blood cells counts
-
Oxygen levels
-
Body temperature
-
Proteins (i.e., hemoglobin)
-
Cancer prevalence
-
Device leakage or failure

PHYSICIANS
-
Early indication of infection
-
Remote patient monitoring
-
Put “eyes and hands” on patients
-
Actionable data
-
Maximize clinic time

PATIENTS
-
Baseline of health before treatment begins
-
Awareness of acceptable symptoms
-
Alert to infection Peace of mind
-
Limits “micro-traumas”

INSURANCE
PAYERS
-
Reduce unexpected hospitalizations
-
Manage costs due to adverse events

PROVIDERS
-
Reduce treatment cancelations or delays
-
Longitudinal data
-
Manage costs Increase efficiency

PHARMA
-
Virtual clinical trial support
-
Passive data collection
-
Adherence and drug efficacy
TEAM

Cathy Skinner, MA
Co-founder/Co-inventor
Chief Executive Officer
-
Entrepreneur with 12 years of startup experience (Thrivors.com and TheArtofWell.com).
-
Nationally recognized Cancer Exercise Specialist with the American College of Sports Medicine.
-
12 years of working face-to-face with cancer patients and survivors providing wellness programs.
-
Invited panelist and guest speaker, Cancer Survivorship Conferences, Employer Benefits, Pharma Patient Advocacy conferences.
-
Former Chair of the Minnesota Cancer Alliance.
-
Board member with one non-profit organization.

Rosanne Welcher, PhD, MBA, RAC
Co-founder/Co-inventor
Chief Operating Officer
-
Award-winning R&D and Business Leader with cross-functional expertise in Medical Devices/IVD business development, product development, regulatory and clinical affairs, quality assurance, manufacturing and commercialization.
-
Over 25 years in med devices/IVD with people management experience.
-
Former CSO Agilent Technologies, Companion Diagnostics.
-
Invited guest speaker, Personalized Medicine, Regulatory/Clinical and IVD conferences.
-
12 issued patents.
-
Board Director with two non-profit organizations.

Mohamed, M Ali, MD, PhD, RDCS
Co-inventor
Engineering and Research
-
Research Asst Professor, University of Illinois at Chicago.
-
Innovator, Biomedical Researcher and Instructor with 20 years’ experience in biomedical technology and cardiovascular medicine.
-
Founder and President, Vivotronix, Inc., providing remote clinical health care and rehabilitation.
-
19 publications and one patent.
ADVISORS

Tufia Haddad, MD
Oncology, Physician and
Patient Perspectives
-
Medical Director, Remote Patient Monitoring, Mayo Clinic Center for Digital Health.
-
Chair of Digital Health for the Department of Oncology.
-
Chair of the Breast Medical Oncology practice at Mayo Clinic.
-
Member of the Mayo Clinic Advisory Board to the Office of Artificial Intelligence.
-
12+ years as medical oncologist.
-
Interests include precision medicine for breast cancer, cancer survivorship, and in the field of digital health, her interest is in the transformation of healthcare delivery models and development of advanced clinical decision support with novel connected health and AI technology solutions.
-
Research and education, providing mentorship to medical students, residents and fellows.

Nancy Lelicoff, BS, MS
Engineering and Management
Regulatory, Quality and Research
-
Healthcare consultant and advisor in regulatory strategy and operations.
-
30+ years experience in the healthcare industry, across all aspects of medical device/IVD product development, registration and maintenance, with increasing levels of leadership.
-
Held executive level positions including former VP of Enterprise Regulatory Affairs, Quality Assurance, and Clinical and Medical Affairs for Agilent Technologies and Sr. VP of Regulatory Affairs, Quality Assurance and Systems Test Engineering for Volcano Corp (now Phillips).

Arvind Raghavan, PhD
Regulatory and Research
-
Cross-functional team leader with 15 years of experience managing the development and testing of therapeutics for multiple disease indications.
-
Demonstrated ability to foster collaborative approaches and innovative solutions, mindful of the big picture while focusing on operational efficiency.
-
Expertise in clinical trial design, monitoring, data analysis and regulatory requirements.

David Radloff
Financing and Strategy
-
30 years of experience in finance, strategy, performance management and leadership
-
Experience in high growth environments as well as process optimization to improve profitability.
-
Former CFO at Hutchison Technology, Inc.
-
Significant experience in bank financing, secured and unsecured public debt as well as equity and equity related financings.
-
Strong relationships with numerous banks, investment banks, and investors.